Debiopharm is the private Swiss developer of the WEE1 inhibitor zedoresertib (Debio 0123) and of dual-payload ADC research.
Zedoresertib is a brain-penetrant, selective WEE1 inhibitor in phase 1/2 as monotherapy and with carboplatin (platinum-resistant ovarian) or with the PKMYT1 inhibitor lunresertib in CCNE1/FBXW7/PPP2R1A-altered tumours (first data AACR 2026). Debiopharm also presented dual-payload ADC and AI-biomarker work at AACR 2026.
Xevinapant was a tablet meant to make head and neck cancer cells easier to kill with chemoradiation by removing the proteins that stop them dying. A promising mid-stage trial was followed by a phase 3 that was stopped in 2024 because it was not working.
Shares WEE1, Ovarian cancer.
Shares WEE1, Ovarian cancer.
Shares WEE1, Ovarian cancer.
Shares Synthetic lethality approaches, TP53.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/